(Seoul=NSP NEWS) = Samsung is investing in American gene-editing company Arbor Biotechnologies through its ‘Life Science Fund’.

The Samsung Life Science Fund is a venture investment fund jointly established by Samsung C&T, Samsung BioLogics, and Samsung Bioepis to develop new technologies and businesses in the life sciences sector. It is managed by Samsung Venture Investment.

Through this investment in Arbor Bio, Samsung plans to explore new business opportunities and explore collaborations for research into core technologies related to gene editing.

Arbor Bio is a bio venture that possesses gene editing technology that recognizes and cuts a specific location in the gene, and can insert, delete, modify, or replace specific genes. This gene editing technology is used to treat and prevent intractable hereditary diseases, blood disorders, cancer, and congenital disorders.
In particular, through AI and machine learning-based prediction techniques and rapid experimental validation, it possesses enzymes of various sizes and functions.